



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday December 24, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
TLXAO	SHARE APPRECIATION RIGHTS	742,992	24/10/2025
TLXAW	PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	1,758,187	24/10/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

24/12/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

24/10/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at <https://ir.telixpharma.com/reports>

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights granted to Telix employees ex-US as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and a two year exercise period following vesting.

Issue details

Number of +securities

742,992

ASX +security code and description

TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025

Date the +securities the subject of this notification were issued

24/10/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No



Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at <https://ir.telixpharma.com/reports>

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights granted to Telix US employees as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and a two year exercise period following vesting. Rights over Telix ordinary shares to be delivered as American Depositary Shares to US domiciled employees.

Issue details

Number of +securities

1,758,187



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,721,355

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,265,004
TLXAO : SHARE APPRECIATION RIGHTS	15,623,553
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	208,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	10,342
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,437,433
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	81,411
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

5.1 Were the securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13